<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
		>
<channel>
	<title>Comments on: Bio Bigwigs from Boston and Beyond Gather in Cambridge to Discuss Future of Drug Development, Venture Capital, and Deals with Pharma</title>
	<atom:link href="http://www.xconomy.com/boston/2009/04/08/bio-bigwigs-from-boston-and-beyond-gather-in-cambridge-to-discuss-future-of-drug-development-venture-capital-and-deals-with-pharma/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.xconomy.com/boston/2009/04/08/bio-bigwigs-from-boston-and-beyond-gather-in-cambridge-to-discuss-future-of-drug-development-venture-capital-and-deals-with-pharma/</link>
	<description>Business + Technology in the Exponential Economy</description>
	<lastBuildDate>Sat, 11 Feb 2012 09:14:03 +0000</lastBuildDate>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.0.4</generator>
	<item>
		<title>By: john</title>
		<link>http://www.xconomy.com/boston/2009/04/08/bio-bigwigs-from-boston-and-beyond-gather-in-cambridge-to-discuss-future-of-drug-development-venture-capital-and-deals-with-pharma/comment-page-1/#comment-53022</link>
		<dc:creator>john</dc:creator>
		<pubDate>Wed, 08 Apr 2009 11:34:15 +0000</pubDate>
		<guid isPermaLink="false">http://www.xconomy.com/?p=19467#comment-53022</guid>
		<description>In light of the fact that Biogenidec codevelops its drugs with other companies and consequently co owns marketing rights isn&#039;t it a bit difficult to dell this company. Take Tysabari for example, co-owned with Elan. Also there areother tie ups with Genentech soon to be Roche/// Also, why is this company woth any more that its current market cap when more efffective or palatable MS treatments are on the horizon, Tysababri&#039;s patent expiration is an issue, it may cause PPL and get taken off the market again, and it has still not hit goals set by  the comapnmny in terms of usage. Add ont this Obama&#039;s push toward &quot;generic biologicals&quot;. So, why is BIIB even woth currentmarket cap???? Or is this Carl Icahn just trying to get his investment back by talking the stock up???</description>
		<content:encoded><![CDATA[<p>In light of the fact that Biogenidec codevelops its drugs with other companies and consequently co owns marketing rights isn’t it a bit difficult to dell this company. Take Tysabari for example, co-owned with Elan. Also there areother tie ups with Genentech soon to be Roche/// Also, why is this company woth any more that its current market cap when more efffective or palatable MS treatments are on the horizon, Tysababri’s patent expiration is an issue, it may cause PPL and get taken off the market again, and it has still not hit goals set by  the comapnmny in terms of usage. Add ont this Obama’s push toward “generic biologicals”. So, why is BIIB even woth currentmarket cap???? Or is this Carl Icahn just trying to get his investment back by talking the stock up???</p>
]]></content:encoded>
	</item>
</channel>
</rss>

